News|Articles|November 18, 2026

FDA Grants Breakthrough Therapy Designation to Daretabart for Newly Diagnosed High-Risk Neuroblastoma

Author(s)OncLive Staff
Fact checked by: Ashling Wahner
Listen
0:00 / 0:00

Key Takeaways

  • Breakthrough therapy designation was supported by NB2012 outcomes, including 73.7% 3-year EFS, 86.0% 3-year OS, and significantly improved early responses versus historical chemotherapy-only comparators.
  • Daretabart targets GD2, is 98% human, includes a K322A mutation to reduce complement-mediated pain, and is produced in YB2/0 cells to reduce fucosylation and enhance ADCC.
SHOW MORE

Phase 2 NB2012 data showed a 3-year event-free survival rate of 73.7% with daretabart plus induction chemotherapy.

The FDA has granted breakthrough therapy designation to daretabart (hu14.18K322A), an investigational anti-GD2 humanized monoclonal antibody, in combination with induction chemotherapy as first-line treatment for pediatric patients with newly diagnosed high-risk neuroblastoma.¹

The designation was supported by findings from the phase 2 NB2012 trial (NCT01857934), a single-arm study of 64 patients.1,2 The 3-year event-free survival (EFS) rate was 73.7% (95% CI, 60.0%-83.4%), and the 3-year overall survival rate was 86.0% (95% CI, 73.8%-92.8%). After 2 induction cycles, 66.7% of evaluable patients (95% CI, 55.0%-78.3%) had a partial response or better vs 39.1% (95% CI, 35.3%-43.0%) of those from a historical group treated with the same chemotherapy without the antibody (P < .0001).² At the end of induction, 60 of 62 evaluable patients (96.8%; 95% CI, 88.8%-99.6%) had achieved a partial response or better, including 40 patients (65%) with a metastatic complete response; no patient had disease progression during induction therapy. Primary tumor volume decreased by a median of 75%.

“We look forward to executing our clinical development strategy, including our ongoing phase 2/3 SHINE study [NCT07549321] in relapsed and refractory disease, together with our future planned induction study, to bring this antibody to the neuroblastoma community,” Simon Ball, president of Renaissance Pharma, stated in a news release.1

What is the mechanism of action of daretabart?

Daretabart is a humanized monoclonal antibody directed against GD2, an antigen that neuroblastoma cells express at high levels on their surface. The antibody retains the binding specificity of dinutuximab (Unituxin), is 98% human, and carries a single point mutation intended to reduce complement-associated pain.² It is produced in a rat myeloma cell line (YB2/0) to reduce fucosylation and enhance antibody-dependent cell-mediated cytotoxicity.

What was the design of the NB2012 trial?

NB2012 was a prospective, open-label, single-arm trial conducted at a single institution. It enrolled children younger than 19 years with newly diagnosed high-risk neuroblastoma, opened in May 2013, and completed therapy for its last patient in July 2019. Patients received 6 cycles of multi-agent induction chemotherapy, with daretabart given at 40 mg/m² intravenously over 4 hours daily on days 2 through 5 of each cycle, along with granulocyte-macrophage colony-stimulating factor and low-dose interleukin-2.

Consolidation therapy consisted of a busulfan and melphalan regimen with autologous hematopoietic stem cell transplant, an additional daretabart cycle with parent-derived natural killer cells when available, and radiation therapy at the end of consolidation. Post-consolidation treatment included daretabart, granulocyte-macrophage colony-stimulating factor, interleukin-2, and isotretinoin. The primary objectives were to compare the response rate after 2 cycles with those from a historical cohort given the same chemotherapy and to estimate EFS. Enrollment was expanded after an interim analysis exceeded the a priori response benchmark.

What is the safety profile of daretabart in neuroblastoma?

The NB2012 trial investigators described the regimen as well tolerated, with opioid infusions adjusted to patient tolerance. Across 379 total cycles, grade 3 or 4 adverse effects that were attributed to antibody infusion during induction occurred in 10% for pain (n = 38), 6% for hypoxia (n = 21), 4% for infusion-related reactions (n = 14), 3% for hypotension (n = 12), and 1% for cough (n = 4).¹ Human antihuman antibody responses developed in 5 of 64 patients (7.8%).²

What are the next steps for developing daretabart for neuroblastoma?

The SHINE study is evaluating daretabart in combination with temozolomide (Temodar) and irinotecan in patients with relapsed or refractory high-risk neuroblastoma.3 The open-label, single-arm study is currently enrolling and is investigating overall response rate and the metastatic complete response rate as primary end points.

References

  1. Renaissance Pharma secures FDA breakthrough therapy designation for daretabart in newly diagnosed high-risk neuroblastoma. News release. Renaissance Pharma. November 16, 2026. Accessed November 18, 2026. https://www.globenewswire.com/news-release/2026/11/16/3403173/0/en/for-investors-and-financial-and-business-media-only-renaissance-pharma-secures-fda-breakthrough-therapy-designation-for-daretabart-in-newly-diagnosed-high-risk-neuroblastoma.html
  2. Furman WL, McCarville MB, Shulkin BL, et al. Improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy: updated results of a phase II study using hu14.18K322A. J Clin Oncol. 2022;40(4):335-344. doi:10.1200/JCO.21.01375
  3. A safety and efficacy study of hu14 in high-risk neuroblastoma patients (SHINE). ClinicalTrials.gov. Updated November 3, 2026. Accessed November 18, 2026. https://clinicaltrials.gov/study/NCT07549321

Related to this article